Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EUC²LID

Financiado

Cerrado

European Lead Factory

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pha... ver más

31/05/2018

BAYER AKTIENGESELL...

197M€

Presupuesto del proyecto: 197M€

Líder del proyecto

BAYER AKTIENGESELLSCHAFT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 30 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2018-05-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

30 Participantes

BAYER AKTIENGESELLSCHAFT

Lider

Leiden University Medical Ce...

N.D. | Participante

ULEI

N.D. | Participante

SANOFIAVENTIS DEUTSCHLAND GM...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EUC²LID European Lead Factory 197M€ Cerrado

PTQ-09-01-01032 Generación de una herramienta de cribado virtual para la ide... 55K€ Cerrado

REMATCH Image based analysis for drug discovery and repurposing 150K€ Cerrado

iDESIGN Delivering Better Starting Points for Drug Discovery New Co... 2M€ Cerrado

BIOMOLECULES DESIGN THROUGH MULTIVARIATE ANAL... BIOMOLECULES DESIGN THROUGH MULTIVARIATE ANALYSIS PROCESS FO... 3M€ Cerrado

ULTIMATE The best online drug discovery platform Building the Ultima... 2M€ Cerrado

Duración del proyecto: 64 meses Fecha Inicio: 2013-01-01
Fecha Fin: 2018-05-31

Líder del proyecto

BAYER AKTIENGESELLSCHAFT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 197M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provide an industry-like small molecule discovery platform to public investigators. It builds on a unique, comprehensive, high-quality compound collection contributed by EFPIA Pparticipants, i.e. the Pharma Consortium Compound Collection totaling over about 300.000 compounds. Screening of these previously safeguarded corporate compound libraries against competitor’s targets and targets from public sources may result in otherwise inaccessible valuable lead structures that could ultimately result in the development of novel treatment options for patients. Academic Participantsa or other eligible bodies (and Contributing Third Parties) will be invited to submit proposals for screening of innovative targets and to suggest the design of new and diverse chemical libraries utilizing novel concepts and strategies. The latter will fuel the generation of a Public Compound Collection that will combine with the Pharma ConsortiumEFPIA Compound Collection to generate the Joint European Compound CollectionLibrary. These public sector contributions will not only provide a constant flow of innovation, but also generate opportunities for future partnerships amongst public Public Participants and private contributors EFPIA Participants on scientific and commercial grounds. EUC2LID’s overarching goal is value creation by screening the Joint European Compound Collection Library against in pPublic and private EFPIA Ttarget Programmes. Based on the successful delivery on its objectives during the IMI funding period, the generation of the high quality Public Compound Collection provides a tangible asset allowing the transition of the European Lead Factory into a novel sustainable business model, facilitating future public-private alliances based on pre-competitive, community-based efforts in early drug research.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores